Edition:
United States

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
4:00pm EDT
Change (% chg)

$0.13 (+8.84%)
Prev Close
$1.47
Open
$1.49
Day's High
$1.63
Day's Low
$1.48
Volume
209,403
Avg. Vol
60,049
52-wk High
$1.80
52-wk Low
$0.77

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics Group Q2 Loss Per Share $0.07
Thursday, 9 Aug 2018 04:46pm EDT 

Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS, BUSINESS PROGRESS AND RECENT ACCOMPLISHMENTS.Q2 LOSS PER SHARE $0.07.SEES FY 2018 REVENUE MORE THAN $20 MILLION.Q2 REVENUE $5.5 MILLION VERSUS I/B/E/S VIEW $5 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.GUIDANCE OF REVENUES FOR YEAR OF OVER $20 MILLION REAFFIRMED.FY2018 REVENUE VIEW $20.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Interpace Diagnostics Announces Expansion Of Labcorp National Agreement
Tuesday, 20 Mar 2018 08:00am EDT 

March 20 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ANNOUNCES EXPANSION OF LABCORP NATIONAL AGREEMENT.INTERPACE DIAGNOSTICS - AGREEMENT WITH LABCORP TO FURTHER EXPAND CO'S NETWORK OF CYTOLOGY PROVIDERS IN SUPPORT OF ITS THYROID MOLECULAR BUSINESS UNIT​.INTERPACE DIAGNOSTICS - ‍ UNDER NEW AGREEMENT, PHYSICIANS WILL BE ABLE TO ORDER BOTH THYROID BIOPSY ANALYSIS AND MOLECULAR TESTING FROM INTERPACE​.  Full Article

Interpace Diagnostics Group Reports Qtrly Loss Per Share ‍$0.19​
Thursday, 15 Mar 2018 04:01pm EDT 

March 15 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, BUSINESS PROGRESS AGAINST PLAN AND RECENT ACCOMPLISHMENTS.Q4 REVENUE $4.4 MILLION VERSUS I/B/E/S VIEW $4.2 MILLION.QTRLY LOSS PER SHARE ‍$0.19​.  Full Article

Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering​
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Interpace Diagnostics Group Inc -:Interpace Diagnostics Group Inc- ‍New York State Department Of Health has reviewed and approved for marketing co's TERT service offering​.  Full Article

Interpace Diagnostics says Q3 sales up 27 pct
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Interpace Diagnostics Group Inc ::Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments.Q3 sales rose 27 percent to $4.2 million.Interpace diagnostics group inc qtrly ‍net loss per diluted share of common stock $0.15​.  Full Article

Interpace Diagnostics ‍launches new lung cancer test MVPdX​
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics Group Inc - ‍Launch of a new lung cancer test MVPdX​.  Full Article

Interpace Diagnostics reports Q2 ‍loss per share from cont ops of $0.65
Thursday, 10 Aug 2017 09:50am EDT 

Aug 10 (Reuters) - Interpace Diagnostics Group Inc ::Interpace Diagnostics Group reports second quarter 2017 financial results, business progress and recent accomplishments.Qtrly ‍loss per share from continuing operations​ $0.65.Qtrly revenue $3.9 million versus $3.6 million​‍​.Qtrly net loss per diluted share of common stock $0.65​.  Full Article

Interpace Diagnostics says Cigna agreed to cover co's ThyGenx test for Cigna members
Thursday, 27 Jul 2017 08:00am EDT 

July 27 (Reuters) - Cigna Corp :Interpace diagnostics group inc - cigna agreed to cover interpace's thygenx test for cigna members nationwide, with coverage effective immediately.  Full Article

Interpace Diagnostics announces national contract with Aetna
Wednesday, 28 Jun 2017 08:15am EDT 

June 28 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics announces national contract with Aetna.Interpace Diagnostics Group -Signed new national contract with Aetna for its THYGENX and Thyramir molecular tests for indeterminate thyroid nodules​.  Full Article

Interpace Diagnostics announces pricing
Friday, 16 Jun 2017 09:00am EDT 

June 16 (Reuters) - Interpace Diagnostics Group Inc ::Interpace Diagnostics announces pricing of $13.7 million underwritten public offering of common stock and common warrants.Interpace Diagnostics Group Inc - pricing of an underwritten public offering of 12.5 million shares of its common stock.Interpace Diagnostics Group Inc - common warrants will be immediately exercisable at a price of $1.25 per share of common stock.  Full Article

BRIEF-Interpace Diagnostics Group Q1 Revenue Rises 39 Percent

* INTERPACE DIAGNOSTICS GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, BUSINESS PROGRESS AND RECENT ACCOMPLISHMENTS